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The LDLR family of proteins is involved in lipoproteins trafficking. While the role of LDLR in
cardiovascular disease has been widely studied, only recently the role of other members of
the LDLR proteins in lipoprotein homeostasis and atherosclerosis has emerged. LDLR,
VLDLR, and LRPs bind and internalize apoE- and apoB-containing lipoprotein, including
LDL and VLDL, and regulate their cellular uptake. LRP6 is a unique member of this family
for its function as a co-receptor for Wnt signal transduction. The work in our laboratory has
shown that LRP6 also plays a key role in lipoprotein and TG clearance, glucose ho-
moeostasis, and atherosclerosis. The role of these receptor proteins in pathogenesis of di-
verse metabolic risk factors is emerging, rendering them targets of novel therapeutics for
metabolic syndrome and atherosclerosis. This manuscript reviews the physiological role of
the LDLR family of proteins and describes its involvement in pathogenesis of hyperlipidemia
and atherosclerosis.
introduction
Lipoprotein transport of cholesterol in
plasma plays a physiological role for es-
sential energy production, cell membrane,
and hormone synthesis. Cells readily utilize
cholesterol by internalizing lipoprotein lig-
ands containing chylomicron, low-density
lipoprotein (LDL†), intermediate-density
lipoprotein  (IDL),  or  very  low-density
lipoprotein (VLDL) mediated by the LDL
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ceptors. Internalized lipoprotein particles
undergo an endocytic process that includes
clustering of lipoprotein receptors in coated
pits, transport to early and late endosomes
followed by hydrolysis in lysosomes, release
of the lipid to cytoplasm, and recycling of
receptors back to cell surface. LDLR-medi-
ated endocytosis has provided much of our
understanding of lipoprotein clearance, and
its defect is a major cause of familial hyper-
lipidemia and a fundamental risk factor for
cardiovascular disease. 
Elevated LDL is a prevalent risk factor for
coronary artery disease and other atheroscle-
rosis diseases, which constitute the largest
cause of all mortalities in the United States [1].
Defect in LDLR is the most common cause of
familial hypercholesterolemia (FH) and pre-
mature coronary artery diseases. The role of
LDLR in cardiovascular diseases has been ex-
tensively studied. However, only recently the
role of other members of the LDLR family of
proteins in lipoprotein homeostasis and ather-
osclerosis has emerged [2-5]. While significant
advances have been made in understanding the
balance  between  cholesterol  synthesis  and
transport, the mechanisms surrounding cho-
lesterol homeostasis and hypertriglyceridemia
remain incompletely understood. Therefore,
this review will provide basic information on
the role of the LDLR family in lipid home-
ostasis and pathogenesis of cardiovascular dis-
ease.
LdLr FamiLy
The LDLR family comprises a group of
endocytic receptors on the cell surface, which
bind and internalize extracellular ligands, in-
cluding lipoproteins, exotoxins, and lipid-car-
rier complexes [6]. Members of the LDLR
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Figure 1. Low-density lipoprotein receptor family. LDLR is the patriarch of the LDLR fam-
ily. Members of the LDLR family share common structural motifs: LDLR type A repeats (re-
sponsible for binding of ligands), epidermal growth factor (EGF)-like domain (involved in
pH-dependent release of ligands in endosome), transmembrane anchor, and cytoplasmic
domain (binding of NPxY and ARH mediates clustering of the receptors into clathrin coated
pit). LDLR, VLDLR, and LRP8 (ApoER2) additionally contain o-link sugar domain outside the
plasma membrane and NPxY motif in the cytoplasmic domain. LRP1 and LRP2 have rela-
tively large extracellular domains. LRP5/6 has PPPSP motif in cytoplasmic domain. family are structurally and functionally re-
lated to LDLR, which is the patriarch of the
entire family. Proteins of the LDLR family
share structurally common motifs (Figure 1):
LDLR type A repeats, epidermal growth fac-
tor (EGF)-like domain, transmembrane an-
chor, and, in certain instances, cytoplasmic
domain.  LDLR  and  VLDLR  additionally
contain o-link sugar domain, located just out-
side of the plasma membrane. LRP1 and
LRP2 (megalin) have relatively large extra-
cellular domains [7]. LDLR type A repeats
are localized to a region at NH2-terminal and
responsible for binding of ligands, including
apoB-100- and apoE-containing lipoprotein.
EGF-like precursor contains multiple EGF
repeats along with a β-propeller domain and
is involved in pH-dependent dissociation of
ligand-receptor  complex.  Transmembrane
domain helps anchor the receptors to the
membrane.  Cytoplasmic  domain  contains
NPxY (Asn-Pro-any amino acid (x)-Tyr)-
containing domain or PPPSP motif (Pro-Pro-
Pro-Ser-Pro)  [7]  and  is  involved  in  the
targeting of receptors to coated pits and signal
transduction.  Differences  in  position  and
number of each domain create the diversity
in LDLR family members. To date, numer-
ous members of the LDLR family are re-
ported that participate in a wide range of
physiological  processes  [8].  In  particular,
LDLR, VLDLR, LRP5/6, LRP1, and LRP2
play a pivotal role in cholesterol homeostasis
and lipid metabolism [9-13].
LdLr
LDLR is a cell membrane glycoprotein
that functions in the binding and internaliz-
ing  of  circulating  cholesterol-containing
lipoprotein particles. LDLR is ubiquitously
expressed and is a key receptor for main-
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Figure 2. cellular cholesterol homeostasis. Vesicular uptake of lipoproteins is essential
for lipoprotein and lipid metabolism. This process is regulated by the LDLR family of pro-
teins. Recognition of apolipoproteins by the receptor at neutral pH initiates the internaliza-
tion, followed by ARH (also known as LDLR adaptor protein) binding of the cytoplasmic NPxY
motif and clustering of receptor-ligand complexes into clathrin-coated pits. Coated vehicle
dispenses to endosomes, in which acidic condition activates the release of internalized lig-
ands from the receptor. Released ligand particles travel further to lysosome, in which ligand
is degraded by enzyme. The receptors recycle back to the cell surface. Internalized choles-
terol reduces cholesterol biosynthesis and LDLR transcription by inhibiting SREBP-2. PCSK9
binds to LDLR, which is targeting LDLR to lysosome for degradation. De novo lipogenesis
is also reduced by inhibition of SREBP-1c. TG undergoes adipogenesis to form lipid droplet. taining  cholesterol  homeostasis  in  mam-
mals. LDLR-mediated endocytosis is essen-
tial for lipoprotein and lipid metabolism [14]
(Figure 2). The clearance of LDL, a major
carrier of cholesterol in human, by LDLR is
extensively studied [14-19]. Recognition of
apoB-100 of LDL particles occurs with a
stoichiometry of a single copy of apoB-100
per one LDL particle per receptor monomer
[20]. VLDL, IDL, high-density lipoprotein
(HDL), and chylomicron remnant are also
recognized by LDLR at neutral pH [21,22].
Receptor-ligand complexes undergo endo-
cytosis via clathrin-coated pits. Coated ve-
hicle dispenses to endosomes with LRP6
and  autosomal  recessive  hypercholes-
terolemia  protein  (ARH,  also  known  as
LDLR  adaptor  protein),  connecting  the
LDLR family protein and the endocytic ma-
chinery; thereby, acidic condition activates
dissociation  of  internalized  ligands.  Re-
leased ligand particles further travel to the
lysosome, in which the ligand is degraded
by enzyme, while the receptors recycle back
to the cell surface. LDLR contains seven
LDLR type A repeats in binding domain, im-
mediately followed by EGF-like modules,
transmembrane anchor, and NPxY-repeats
containing cytoplasmic domain. LDL parti-
cles trigger three steps after internalization:
1) reducing gene expression of 3-hydroxy-
3-methylglutaryl-CoA reductase (HMGCR)
to suppress cholesterol biosynthesis; 2) en-
hancing  activity  of  acyl-CoA  cholesteryl
acyl transferase (ACAT) to reduce toxic free
cholesterol; and 3) suppressing LDLR syn-
thesis to reduce LDL uptake via SREBPs
[23-25].
Impaired  LDLR  function  by  genetic
mutations results in a condition with ex-
tremely elevated serum LDL levels and early
onset atherosclerosis known as familial hy-
percholesterolemia (FH) [26]. The preva-
lence is 1:500 for heterozygote and 1 in a
million for homozygote FH [27]. While nor-
mal fibroblasts have high cell surface bind-
ing affinity for LDL via LDLR, cultured
fibroblasts  from  FH  patient  fail  to  clear
serum LDL, thus causing elevated serum
LDL [16,19]. Patients homozygote for LDLR
mutation have serum LDL levels that are as
high as 800 mg/dL and show widespread ac-
cumulation of cholesterol-mediated athero-
matous plaques in their coronary arteries,
aorta, and aortic valves [18]. Heterozygote
LDLRmutation carriers have typically twice-
elevated plasma LDL concentration and two-
fold increase risk for coronary artery disease
compared to the general population. Most
guidelines suggest adjustment of LDL levels
to less than 100 mg/dL in individuals with
two or more risk factors for coronary artery
disease and 70 mg/dL for patients with es-
tablished coronary artery disease. Approxi-
mately  50  percent  of  heterozygote  FH
patients develop various forms of cardiovas-
cular disease in the fourth or fifth decades
[17]. LDLR mutations can be classified into
five groups based on the functional charac-
teristics of the encoded proteins: 1) null alle-
les  causing  receptor  synthesis-defect;  2)
transport-defective alleles with defect in tar-
geting receptor to cell surface; 3) binding-de-
fective alleles that encode proteins that fail
to bind ligands; 4) internalization-defective
alleles that encode proteins that fail to inter-
act with clathrin coated pit; and 5) recycling-
defective alleles, which remain undissociated
in the acidic pH of lysosomes [28]. 
Ldlr-/- mice fed a 1.5 percent high cho-
lesterol diet not only exhibit enhanced hyper-
lipidemia  and  increased  generation  of
reactive oxygen species, but also alter vascu-
lar structure along with increased collagen
content [29,30]. LDLR gene transfer by in-
travenous injection of adenovirus to Ldlr-/-
mice reduces plasma LDL and VLDL cho-
lesterol [10]. Autosomal recessive hypercho-
lesterolemia clinically resembles FH but is
caused by mutations in an LDLR adaptor pro-
tein,  which  is  named  after  the  disorder
(ARH). LDLR adaptor protein deficient mice
(Arh-/-) have impaired LDLR internalization
in a variety of tissues such as the liver and ex-
hibit a major defect in LDL clearance [31,32].
Proprotein convertase subtilisin/kexin type 9
(PCSK9) is a protein secreted from the hepa-
tocytes, which undergo protein-protein inter-
action  with  LDLR,  resulting  in  their
degradation [33]. Gain of function in humans
causes  hypercholesterolemia,  and  loss  of
function is associated with low LDL choles-
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RNAi  targets  PCSK9,  specifically  lower
plasma  LDL  cholesterol,  by  preventing
LDLR degradation in vivo and in vitro [34].
Similarly, inhibition of PCSK9 effectively in-
creases hepatic LDLR expression and re-
duces LDL cholesterol in plasma in mice
[35]. In sum, LDLR is a pivotal receptor for
endocytic machinery and plays a pivotal role
in maintaining cholesterol homeostasis. De-
fect in LDLR function or expression triggers
elevated LDL cholesterol and results in major
atherosclerotic diseases.
VLdLr
VLDLR, along with LDLR and LRP1,
is the main endocytic receptor recognizing
apoE-containing  lipoproteins.  VLDLR  is
widely expressed in adipose tissues, skeletal
muscle, heart, and endothelial cells of capil-
laries and small arterioles but not in hepato-
cytes in which LDLR is widely distributed
[36]. In contrast, LRP8 (ApoER2), which has
50 percent homology with VLDLR, is mainly
expressed in brain, testis, and placenta [37].
VLDLR primarily modulates the extra-he-
patic metabolism of TG-rich lipoprotein. The
structure of VLDLR is highly homologous to
that of LDLR (Figure 1). VLDLR contains
eight cysteine-rich LDLR type A repeat do-
mains compared to seven in LDLR. ApoE-
containing VLDL not only binds to VLDLR,
but to LDLR, LRP8, LRP1, LRP2, and likely
LRP6 as well. Unlike LDLR, VLDLR is not
linked to a feedback mechanism for its ex-
pression in response to intracellular VLDL
[38]. VLDLR expression is directly regulated
by PPAR-γ. Accordingly, pioglitazone (ago-
nist of PPAR-γ) increases Vldlr mRNA ex-
pression  and  protein  level  in  3T3-L1
preadipocytes  (mouse  fibroblasts).  Mice
treated with pioglitazone exhibit enhanced
conversion of plasma TG to epididymal fat.
This response is absent in VLDLR deficient
mice, which implies that VLDLR plays a key
role in fat deposition [39].
VLDLR has an important function in
postprandial chylomicron and VLDL clear-
ance  by  up-regulating  lipoprotein  lipase
(LPL)-mediated TG hydrolysis and direct up-
take of TG-rich lipoproteins in endothelial
cell [3]. VLDL and LPL have similar distri-
bution patterns in peripheral tissues. Vldlr-/-
mice have diminished LPL expression, which
causes increased plasma TG; Vldlr-/- mice ex-
hibit 250 percent higher TG levels and 60
percent lower chylomicron uptake compared
to those in wildtype [3]. Therefore, VLDLR
actively functions as a lipoprotein receptor by
uptake of TG-rich VLDL (but not LDL) and
provides sufficient energy substrates in pe-
ripheral tissues. Vldlr-/- mice also exhibit low
adipose  tissue  mass  without  significant
change in their plasma lipoprotein profiles.
This latter finding is due to the fact that HDL
has the greatest contribution to lipoproteins
in mice [11]. Conversely, adenovirus transfer
of Vldlr cDNA to the liver increases choles-
terol clearance by binding apoE-containing
lipoprotein in mice model [40,41]. Expres-
sion of VLDLR increases with fasting, which
also increases fatty acid binding protein and
acetyl CoA synthase to provide a sufficient
energy source for vital organs such as the
heart and brain [42]. The exact molecular
mechanisms of VLDLR function in lipopro-
tein metabolism are not fully understood. 
Low-density Lipoprotein-
reLated protein 6 (Lrp6)
LRP6 is a member of the LDLR family,
which together with LRP5 has the unique
structure and function as an essential co-re-
ceptor for Wnt/β-catenin signaling [43]. In
particular, extracellular domain of LRP6 has
three types of subdomains, including LDLR
type  A  repeats,  EGF-like  domain,  and
YWTD-type β-propeller domain (Figure 1).
LRP6 is comprised of three large clusters of
ligand binding repeats, each with ligand bind-
ing functions with Wnt, DKK1, and lipopro-
tein particles, whereas LDLR and VLDLR
contain only a single ligand-binding repeat
cluster. Upon binding of Wnt to cell surface
receptor Frizzled and its co-receptors LRP5/6
complex, the cytoplasmic tail of LRP6 is
phosphorylated by CK1 and glycogen syn-
thase kinase 3β (GSK-3β), leading to Dv1 re-
cruitment and binding of Axin complex. This
results in stabilization of β-catenin and its
translocation onto the nucleus, where it binds
23 Go and Mani: LDLR family and cholesterol metabolismto transcription factors such as T cell factor
(TCF)/lymphoid enhancer factor (LEF) and
stimulates various gene expressions [44].
A missense mutation in LRP6at a highly
conserved residue of an EGF domain has
been  linked  to  autosomal-dominant  early
onset of cardiovascular disease and metabolic
syndrome traits, including hyperlipidemia, di-
abetes, osteoporosis, and hypertension [2].
Patients who carry the LRP6R611Cmutation ex-
hibit elevated serum LDL cholesterols, TG,
and fasting glucose level, which together con-
stitute the metabolic syndrome, a major risk
factor for atherosclerosis and myocardial in-
farction. These associations strongly suggest
a pluripotent effect of this gene. 
Common  genetic  variations  within
LRP6 also have been associated with plasma
LDL levels, implicating LRP6 as a potential
regulator of lipid metabolism and a novel tar-
get for pharmacological interventions [45].
Liu et al. [46] have demonstrated that an in-
tact LRP6 function is essential for normal
LDL clearance, whereas the LRP6R611C muta-
tion results in reduced LRP6 membrane ex-
pression  and  impaired  LDL  clearance.
Splenic macrophages of LRP6+/-mice display
reduced LDL uptake compared to wild-type
mice. Peripheral B-lymphocytes of LRP6R611C
mutation carriers exhibit significantly im-
paired LDL internalization despite similar
affinities for apoB at neutral pH. LRP6 aug-
ments cellular LDL binding and uptake, both
in LDLR dependent and independent manner.
According to Ye et al. [9], LRP6 co-localizes
with LDLR and regulates its clathrin-depen-
dent internalization (Figure 2). LRP6 forms
a complex with clathrin and ARH and is re-
quired for LDL clearance via clathrin-medi-
ated  internalization.  Human  fibroblast  of
LRP6R611C mutation carriers show impaired
function of the LDLR-dependent endocyto-
sis. Preliminary work in our laboratory has
shown that LRP6 not only regulates LDL and
TG clearance, but it is also involved in syn-
thesis of TG and fatty acids.
Keramati et al. have reported increased
expression and co-localization of LRP6 with
PDGF receptor β in human atherosclerotic
coronary arteries [47]. Wild-type LRP6 forms
a complex with platelet-derived growth factor
receptor (PDGFR)-β and triggers its lysoso-
mal degradation. This effect reduces vascular
smooth muscle cell proliferation and is con-
sidered  protective  against  atherosclerosis.
Conversely, the LRP6R611C mutation signifi-
cantly  activates  PDGF  signaling  and  in-
creases PDGF-dependent cell-cycle activity
in smooth muscle cell. This causes increased
smooth muscle proliferation, which is an im-
portant component of atherosclerosis devel-
opment.
Low-density Lipoprotein-
reLated protein 1
LRP1 (also known as a2-macroglobulin
receptor or CD91) is ubiquitously expressed
in most tissues and abundantly exists in the
liver and brain. LRP1 is composed of a large
ligand binding subunit (515-kDa), which rec-
ognizes more than 40 ligands, and a relatively
small  transmembrane  fragment  (85-kDa)
(Figure 1). LRP1 harbors ligands as a cargo
transporter  and  modulates  physiologic
processes including inflammatory response
in  the  lung  [48],  amyloid  ￟42  uptake  in
blood-brain barrier [49], and clearance of fac-
tor VIII in the blood coagulation process [50].
A number of proteases and protease inhibitor
complexes are regulated by LRP1-mediated
pathway [51]. LRP1 also functions as a re-
ceptor for removal of apoE-rich chylomicron
remnant; i.e., it shuttles dietary lipid from in-
testine to liver. LRP1 is likewise involved in
the clearance of apoE-rich lipoprotein, in-
cluding VLDL in liver, smooth muscle cells,
and macrophages. 
LRP1 is essential for the maintenance of
vascular integrity during embryonic develop-
ment. In adult life, LRP1 plays an essential
role in protecting against atherosclerosis by
reducing  vascular  smooth  muscle  cell
(VSMC) proliferation and regulating levels
of PDGF receptor in the vessel wall [52].
Lrp1-/- mice increase susceptibility to devel-
opment of atherosclerotic lesions by greater
secretion of apoE, reduced uptake of remnant
in macrophages, and reduced HDL plasma
level  [4].  LRP1  inactivation  likewise  in-
creases postprandial dyslipidemia and ather-
osclerosis in Lrp1-/- mice [53]. In addition to
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fatty acid uptake. Lrp1-/- fibroblasts decrease
the uptake of fatty acid, resulting in an in-
crease of free fatty acid and redistribution to
the liver [12]. Statin intervention in rats has
shown to up-regulate both LRP1 and LDLR
via activated SREBP-2 related pathway, re-
sulting in protection against atherosclerosis
[54]. 
Low-density Lipoprotein-
reLated protein 2, megaLin
LRP2, also named megalin for its huge
molecular  structure,  is  a  member  of  the
LDLR family that is abundantly expressed in
different epithelial cell types [55]. LRP2 is an
endocytic receptor for diverse ligands, in-
cluding  lipoprotein,  steroid,  and  retinoid.
Renal re-absorption of a variety of molecules,
in particular vitamin B12 and HDL, is an im-
portant function of LRP2, which is positively
regulated by PPAR-α/β [13]. LRP2 is com-
posed of extracellular ligand binding domain,
transmembrane fragment, and cytoplasmic
tail containing three NPxY motifs (a total mo-
lecular weight of 517 kDa) (Figure 1). Simi-
lar to LRP1, receptor function of LRP2 is
connected to proteolysis between the trans-
membrane anchor and cytoplasmic motif.
Ligand binding to LRP2 triggers shedding of
its ectodomain by protein kinase C (PKC)-in-
duced matrix metalloproteinase. Cytoplasmic
C-terminal fragment is cleaved by β-secre-
tase, resulting in its release into the cyto-
plasm, whereby it presumably functions as a
transcriptional regulator in the nucleus [56].
Similar to LRP5/6, LRP2 needs mesoderm
development (MESD) chaperone, which pre-
vents misfolding of LRP2 [57]. LRP2 is in-
volved  in  embryonic  renal  development,
including vitamin D homeostasis, sex hor-
mone signaling, and holoprosencephaly [58-
60]. Genetic variations in LRP2 have been
associated with elevated total cholesterol and
LDL  in  patients  with  dyslipidemia  [61].
LRP2 harbors cubilin, which bind to HDL,
thus providing an important role in endocy-
tosis of HDL cholesterol [5]. The role of
LRP2 in dyslipidemia and atherosclerosis is
far from complete. 
Low-density Lipoprotein-
reLated protein 5
LRP5 structure is analogous to that of the
LRP6 and similarly functions as a co-recep-
tor for Wnt/β-catenin signaling. LRP5 is well
known for its affect on bone mass density and
mineralization. Loss of function mutations are
associated with osteoporosis pseudoglioma
[62], and gain of function mutations are asso-
ciated with high bone density [63]. LRP5 may
be involved in mineralization of the athero-
sclerotic lesion [64]. Apoe-/- mice fed with
western diet (42 percent kcal from fat and 0.2
percent cholesterol) show increased LRP5 ex-
pression. Interestingly, Apoe-/-mice on a West-
ern diet develop calcified plaque, while Lrp5-/-
or Apoe-/-, Lrp5-/-double knockouts have no or
minimal calcified lesions [65]. Accordingly,
Ldlr-/- mice fed either chow (18 percent kcal
from fat) or Western diet have high expression
levels of Lrp5 in aortic tissue [66]. Lrp5-/-mice
exhibit decreased hepatic clearance of chy-
lomicron remnants, plasma cholesterol levels,
and impaired insulin secretion [67]. Further
investigation is necessary to clarify the role of
LRP5 in calcification of atheromatous plaque
and lipoprotein endocytosis. 
concLusions
Members of the LDLR family of pro-
teins dynamically bind and internalize apoE-
and apoB-containing lipoprotein, including
LDL, VLDL, and chylomicron remnant. De-
fect in these receptors is associated with dys-
lipidemia and atherosclerosis in mammals.
LDL defect is the most common cause of fa-
milial hypercholesterolemia, which is associ-
ated  with  very  high  plasma  LDL  levels,
accounted for by impaired LDL clearance and
enhanced cholesterol biosynthesis. VLDLR
modulates the binding and uptake of apoE-
containing lipoprotein, including chylomi-
cron and VLDL, and regulates TG level in
plasma. LRP6, well known as co-receptor for
Wnt signal pathway, is a unique member of
this receptor family. Recent work in our lab-
oratory and by others has shown that LRP6
also functions as a regulator of cholesterol
and lipid homeostasis, glucose metabolism,
and blood pressure. Preliminary work in our
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only regulates LDL and TG uptake, but it is
also involved in synthesis of TG and fatty
acids. In addition, LRP6 plays a major role in
vascular integrity and protection against ath-
erosclerosis, in part by its anti-proliferative
effects. Therefore, LDLR family members
are principal targets of novel therapeutics for
metabolic risk factors and diseases. While
current lipid lowering drugs such as statins
have been very effective in reducing serum
LDL levels in the general population, there
remain a significant number of patients with
extremely high LDL levels that show no or
modest responses. Furthermore, these drugs
have no or small effects on serum TG and
HDL. Inflammatory processes and vascular
smooth muscle cell proliferation also play a
pivotal role in cardiovascular diseases. There-
fore, other members of the LDLR family may
be targets of novel therapeutic for the most
common form of hyperlipidemia known as
combined familial hyperlipidemia. For in-
stance, targeting LRP6 may reverse diverse
pathophysiological processes in atheroscle-
rotic diseases, including increased TG/VLDL
synthesis, elevated lipolysis, decreased LDL
clearance, and enhanced VSMC proliferation.  
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